1
|
HEPARIN AS AN ANTIBACTERIAL COATING ON BIODEGRADABLE URETERAL STENTS: EXPERIMENTAL STUDY OF BRAIDSTENT®-H. Br J Surg 2021. [DOI: 10.1093/bjs/znab160.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
INTRODUCTION
The aim of this study is to assess the effectiveness of heparin to inhibit the development of early bacteriuria as a coating for biodegradable ureteral stents.
MATERIAL AND METHODS
The BraidStent®-H biodegradable stent, whose heparin coating is incorporated by dip coating, was chosen for this study. Twenty-four swine were randomly divided into two groups: 12 animals underwent unilateral placement of the BraidStent®-H and 12 were fitted with a standard double-j stent (DJS). Bacteriuria is comparatively analyzed over time by consecutive urine sampling at 0, 1, 3, 6, 12, 24 and 48 hours. In addition, the concentration of heparin released in vitro in artificial urine at 0, 3, 6, 12, 24, 48, 72, 92 and 120 hours is determined via ELISA.
RESULTS
BraidStent®-H generates a significantly lower bacteriuria rate than a DJS at 6 and 12 hours. Heparin coating shows a significant delaying effect on the onset of bacteriuria, reaching 100% of the animals at 48 hours, compared to the DJS, which takes place at 6 hours. ELISA results reveal the presence of heparin in urine for a total of 72 hours. The coating does not affect the degradation of the device, which is completed at 6 weeks.
CONCLUSIONS
Heparin evidences an effective inhibition of early bacteriuria, showing its potential as an antibacterial coating for biodegradable ureteral stents. Future studies should focus on the development of long-term heparin coatings for biodegradable materials.
Collapse
|
2
|
EVALUATION OF THE RELEASE RATE OF A CHEMOTHERAPEUTIC AGENT INCORPORATED AS A COATING ON A BIODEGRADABLE URETERAL STENT. IN VITRO STUDY. Br J Surg 2021. [DOI: 10.1093/bjs/znab160.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
INTRODUCTION
To assess the release rate of Mitomycin C (MMC) after its adherence to a biodegradable ureteral stent (BraidStent™-MMC) by dip coating in order to evaluate its potential application as an adjuvant treatment for upper tract urothelial carcinoma.
MATERIAL AND METHODS
The dip coating technique is applied to a total of 10 fragments of the BraidStent™ catheter which has a polymeric matrix as a coating. Each 3 cm fragment is immersed 10 times in pure MMC crystallising in methanol and finally obtaining the formation of microlayers on its surface. After drying, each fraction of the stent is immersed in 5 ml of artificial urine to study its interaction with this medium. The samples remain in an orbital shaker at 36ºC and the medium is exchanged under sterile conditions after 12, 24, 48, 48, 72, 96 and 120h. At each replacement, the remaining urine is analysed by HPLC-DAD to quantify the presence of the cytotoxic agent.
RESULTS
During the first 12h, MMC is completely released reaching a mean concentration of 52.22 mg/L. Comparing this result with those previously obtained with the first BraidStent ™ -MMC formulation (10.82mg/L), it is determined that this technique allows to increase the release rate up to 5 times.
CONCLUSIONS
The release rate of Mitomycin C from a biodegradable ureteral stent is increased by integrating a polymeric matrix with microlayers in its coating. Further trials are needed to achieve the therapeutic dose for clinical application in oncology patients.
Collapse
|